|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07B2200/05 | (2013.01) |
| C07C 229/08 | (2006.01) | ||
| C07C 229/22 | (2006.01) | ||
| C07C 229/36 | (2013.01) | ||
| A61K 31/223 | (2006.01) | ||
| A61K 31/216 | (2013.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61K 31/198 | (2013.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61P 1/14 | (2018.01) | ||
| A61P 11/02 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 25/02 | (2018.01) | ||
| A61P 25/04 | (2018.01) | ||
| A61P 25/16 | (2018.01) | ||
| A61P 25/18 | (2018.01) | ||
| A61P 25/20 | (2018.01) | ||
| A61P 25/24 | (2018.01) | ||
| A61P 25/28 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 9/02 | (2018.01) | ||
| A61P 9/04 | (2018.01) | ||
| A61P 9/10 | (2018.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 3611159 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19188210.9 |
| Date of filing the European patent application | 2014-07-08 | |
| (97) | Date of publication of the European application | 2020-02-19 |
| (45) | Date of publication and mention of the grant of the patent | 2023-01-25 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201361843549 P | 2013-07-08 | US | |
| 201462010098 P | 2014-06-10 | US |
| (72) |
GOLDSTEIN, David, S. , US
HOLMES, Courtney , US
ALKEN, Rudolf-Giesbert , US
SCHNEIDER, Frank , US
ZHANG, Chengzhi , US
|
| (73) |
Auspex Pharmaceuticals, Inc. ,
400 Interpace Parkway, Parsippany NJ 07054,
US
The U.S.A. as represented by the Secretary, Department of Health and Human Services , Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325 MSC 7660, Bethesda, MD 20892-7660, US |
| (54) | DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS |
| DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS |